Last Close
Apr 08  •  04:00PM ET
0.5459
Dollar change
-0.0040
Percentage change
-0.73
%
Index
-
P/E
-
EPS (ttm)
-1.19
Insider Own
8.10%
Shs Outstand
39.98M
Perf Week
-0.26%
Market Cap
21.82M
Forward P/E
-
EPS next Y
-0.53
Insider Trans
0.31%
Shs Float
36.74M
Perf Month
-47.00%
Enterprise Value
18.38M
PEG
-
EPS next Q
-0.33
Inst Own
19.96%
Perf Quarter
-45.41%
Income
-7.58M
P/S
2.31
EPS this Y
-41.38%
Inst Trans
0.33%
Perf Half Y
-67.11%
Sales
9.44M
P/B
1.29
EPS next Y
35.77%
ROA
-24.22%
Perf YTD
-44.70%
Book/sh
0.42
P/C
4.31
EPS next 5Y
-0.57%
ROE
-2951.24%
52W High
3.13 -82.56%
Perf Year
-53.34%
Cash/sh
0.13
P/FCF
-
EPS past 3/5Y
63.79% 45.78%
ROIC
-128.73%
52W Low
0.49 11.34%
Perf 3Y
-95.53%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
-2.42% -2.71%
Gross Margin
97.73%
Volatility
8.92% 11.04%
Perf 5Y
-99.77%
Dividend TTM
-
EV/Sales
1.95
EPS Y/Y TTM
83.03%
Oper. Margin
-348.43%
ATR (14)
0.07
Perf 10Y
-99.67%
Dividend Ex-Date
-
Quick Ratio
0.49
Sales Y/Y TTM
-13.43%
Profit Margin
-80.29%
RSI (14)
27.84
Dividend Gr. 3/5Y
- -
Current Ratio
0.49
EPS Q/Q
198.04%
SMA20
-22.70%
Beta
3.19
Payout
-
Debt/Eq
0.30
Sales Q/Q
-65.98%
SMA50
-38.98%
Rel Volume
4.51
Prev Close
0.55
Employees
24
LT Debt/Eq
0.08
SMA200
-59.49%
Avg Volume
310.90K
Price
0.55
IPO
Aug 01, 2000
Option/Short
No / Yes
Trades
Volume
1,400,892
Change
-0.73%
Date Action Analyst Rating Change Price Target Change
May-19-25Resumed H.C. Wainwright Buy $17
Nov-17-23Initiated Truist Buy $26
Apr-04-22Downgrade Raymond James Outperform → Mkt Perform
Oct-13-21Initiated Raymond James Outperform $15
Mar-25-21Initiated B. Riley Securities Buy $19
Jul-29-20Initiated Laidlaw Buy $5
Jul-17-20Initiated Cantor Fitzgerald Overweight $4
Oct-24-17Initiated Guggenheim Buy $7
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $3
Nov-09-15Reiterated ROTH Capital Buy $6 → $5
Mar-19-26 11:02PM
08:12PM
04:11PM
04:00PM
Mar-12-26 04:27PM
08:00AM Loading…
Jan-09-26 08:00AM
Jan-07-26 08:45AM
Dec-09-25 08:00AM
Nov-14-25 09:26AM
Nov-07-25 12:02AM
Nov-06-25 05:10PM
04:08PM
04:00PM
Oct-30-25 04:00PM
Oct-03-25 04:00PM
10:43AM Loading…
Sep-02-25 10:43AM
Aug-06-25 11:00AM
Aug-05-25 09:10AM
08:08AM
08:00AM
Aug-04-25 10:13AM
Jul-29-25 08:30AM
Jul-02-25 08:32AM
May-07-25 03:07AM
May-06-25 06:16PM
09:05AM
08:13AM
08:00AM
May-05-25 10:26AM
May-01-25 10:01AM
08:00AM Loading…
Apr-29-25 08:00AM
Apr-12-25 11:00AM
Apr-02-25 04:05PM
Apr-01-25 03:01AM
01:42AM
Mar-31-25 09:59AM
08:16AM
08:00AM
Mar-28-25 04:07PM
Dec-10-24 08:00AM
Nov-15-24 02:37AM
02:07AM
Nov-14-24 09:10AM
08:09AM
08:00AM
Nov-13-24 07:31AM
Nov-07-24 08:00AM
Nov-02-24 11:20AM
Oct-29-24 06:04AM
Oct-09-24 03:42PM
Sep-23-24 08:30AM
Sep-17-24 07:30AM
Sep-04-24 08:00AM
Aug-01-24 09:10AM
08:07AM
08:00AM
Jul-25-24 08:00AM
Jul-10-24 07:30AM
Jul-09-24 12:00PM
Jul-08-24 07:30AM
May-14-24 04:00PM
May-10-24 08:00AM
May-08-24 11:39AM
May-07-24 12:53PM
08:08AM
08:00AM
Apr-30-24 08:00AM
Apr-05-24 08:43AM
07:30AM
Apr-04-24 07:30AM
Feb-09-24 10:10AM
Feb-08-24 08:11AM
08:00AM
Feb-01-24 08:00AM
Jan-05-24 08:00AM
Dec-12-23 08:00AM
Dec-11-23 08:00AM
Dec-06-23 08:00AM
Dec-05-23 08:00AM
Nov-03-23 10:26AM
06:03AM
Nov-02-23 08:19AM
08:00AM
Oct-30-23 10:00AM
Oct-26-23 08:30AM
Oct-06-23 08:56AM
Sep-22-23 03:15AM
Sep-12-23 08:00AM
Sep-06-23 08:13AM
Aug-05-23 05:57AM
Aug-03-23 05:45PM
04:43PM
04:01PM
Jul-27-23 06:25PM
Jul-06-23 08:01AM
08:00AM
Jun-30-23 06:50AM
Jun-06-23 06:54AM
May-15-23 11:33AM
May-05-23 07:30AM
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KAITIN KENNETH IDirectorMar 31 '26Buy0.5510,0005,48711,407Apr 01 07:51 AM